A proof of concept 'phase zero' study of neurodevelopment using brain organoid models with Vis/near-infrared spectroscopy and electrophysiology.
A proof of concept 'phase zero' study of neurodevelopment using brain organoid models with Vis/near-infrared spectroscopy and electrophysiology.
复制标题
使用VIS/近红外光谱和电生理学的脑类器官模型对神经发育的概念验证。
DOI:
10.1038/s41598-020-77929-8
复制
发表时间:
2020-12-02
影响因子:
4.6
通讯作者:
Stachowiak MK
中科院分区:
文献类型:
--
作者:
Dutta A;Karanth SS;Bhattacharya M;Liput M;Augustyniak J;Cheung M;Stachowiak EK;Stachowiak MK
Homeostatic control of neuronal excitability by modulation of synaptic inhibition (I) and excitation (E) of the principal neurons is important during brain maturation. The fundamental features of in-utero brain development, including local synaptic E–I ratio and bioenergetics, can be modeled by cerebral organoids (CO) that have exhibited highly regular nested oscillatory network events. Therefore, we evaluated a 'Phase Zero' clinical study platform combining broadband Vis/near-infrared(NIR) spectroscopy and electrophysiology with studying E–I ratio based on the spectral exponent of local field potentials and bioenergetics based on the activity of mitochondrial Cytochrome-C Oxidase (CCO). We found a significant effect of the age of the healthy controls iPSC CO from 23 days to 3 months on the CCO activity (chi-square (2, N = 10) = 20, p = 4.5400e−05), and spectral exponent between 30–50 Hz (chi-square (2, N = 16) = 13.88, p = 0.001). Also, a significant effect of drugs, choline (CHO), idebenone (IDB), R-alpha-lipoic acid plus acetyl-l-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25.44, p = 1.2492e−05), spectral exponent between 1 and 20 Hz (chi-square (3, N = 16) = 43.5, p = 1.9273e−09) and 30–50 Hz (chi-square (3, N = 16) = 23.47, p = 3.2148e−05) in 34 days old CO from schizophrenia (SCZ) patients iPSC. We present the feasibility of a multimodal approach, combining electrophysiology and broadband Vis–NIR spectroscopy, to monitor neurodevelopment in brain organoid models that can complement traditional drug design approaches to test clinically meaningful hypotheses.
登录
查看更多内容
影响因子:
16.2
作者:
Beckervordersandforth R;Ebert B;Schäffner I;Moss J;Fiebig C;Shin J;Moore DL;Ghosh L;Trinchero MF;Stockburger C;Friedland K;Steib K;von Wittgenstein J;Keiner S;Redecker C;Hölter SM;Xiang W;Wurst W;Jagasia R;Schinder AF;Ming GL;Toni N;Jessberger S;Song H;Lie DC
通讯作者:
Lie DC
影响因子:
16.2
作者:
Chen G;Zhang Y;Li X;Zhao X;Ye Q;Lin Y;Tao HW;Rasch MJ;Zhang X
通讯作者:
Zhang X
DOI:
10.1038/nrn3241
发表时间:
2012-05-18
期刊:
Nature reviews. Neuroscience
影响因子:
--
作者:
Buzsáki G;Anastassiou CA;Koch C
通讯作者:
Koch C
影响因子:
4.5
作者:
Albinana, E.;Luengo, J. G.;Hernandez-Guijo, J. M.
通讯作者:
Hernandez-Guijo, J. M.
影响因子:
3.4
作者:
Cserép C;Pósfai B;Schwarcz AD;Dénes Á
通讯作者:
Dénes Á